Compulsory Licensing: EU Council Backs Stronger IP Protections

The R&D-based pharma industry has welcomed the “more careful and considered approach” taken by EU ministers to the European Commission’s proposed compulsory licensing system, but says there is room for further improvement.

IP Intellectual Property or Internet protocol text made from stones on sea beach
The pharma industry says compulsory licensing will impair intellectual property protections • Source: Shutterstock

The Council of the EU has adopted its negotiating position on the draft Regulation on EU-level compulsory licensing, saying it wants to strengthen the rights of intellectual property holders and stressing the “last-resort” nature of compulsory licensing.

The council’s “negotiating mandate,” which will form the basis of talks with the European Parliament on the draft regulation, also...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography